PL EN


Preferences help
enabled [disable] Abstract
Number of results
2018 | 100 | 61-73
Article title

The comparison of tenecteplase and alteplase in acute stroke treatment: meta-analysis of 5 randomized clinical trials

Content
Title variants
Languages of publication
EN
Abstracts
EN
Thrombolysis with the use of intravenously administrated alteplase is the only approved thrombolytic treatment of acute ischemic stroke. Tenecteplase is a fibrinolytic protein bioengineered from human tissue plasminogen activator with higher fibrin specificity, enhanced affinity to fibrin-rich clots, faster clot lysis and prolonged plasma half-life. The aim of this study was to determine which thrombolytic therapy (tenecteplase versus alteplase) provides better efficacy and safety outcomes. Eligible studies for meta-analysis published from their inception to May 2018 were identified through a search of PubMed database and two clinical trial registries websites: ClinicalTrials.gov and EU Clinical Trials Register. A meta-analysis was conducted with the use of Statistica software version 13.1. Five studies comprising 1529 patients were included. Tenecteplase 0,25mg/kg administration resulted in significantly higher number of patients with excellent score (0-1) in modified Rankin Scale at 90 days compared to alteplase group (RR 1,30, p=0,0215, 95% CI 1,04–1,62). Additionally, more patients treated with tenecteplase 0,25 mg/kg tended to develop favorable score changes in NIHSS at 24 hours after stroke onset (>8 point improvement, scale quantifying stroke severity) compared to alteplase treatment (RR 1,60, p=0,0545, 95% CI 0,99–2,58). No above correlation were observed in higher dose of tenecteplase group (0,4 mg/kg). There were no significant differences in the frequency of symptomatic intracerebral hemorrhage (ICH) and the mortality rates within 90 days after stroke onset in comparison of tenecteplase and alteplase groups. Tenecteplase 0,25 mg/kg administration in acute ischemic stroke resulted in better functional outcome at 90 days after ischemic stroke onset and tended to restrict the severity of stroke at 24 hours in NIHSS compared to alteplase 0,9 mg/kg. The frequency of symptomatic ICH occurrence and mortality within 3 months between tenecteplase and alteplase were comparable.
Discipline
Year
Volume
100
Pages
61-73
Physical description
Contributors
  • Chair and Department of Neurology, Medical University of Lublin, Poland
  • Chair and Department of Neurology, Medical University of Lublin, Poland
  • Chair and Department of Neurology, Medical University of Lublin, Poland
  • Department of Cancer Genetics with Cytogenetics Laboratory, Medical University of Lublin, Poland
author
  • Chair and Department of Neurology, Medical University of Lublin, Poland
References
  • [1] M. Goyal, M.D. Hill, J.L. Saver, M. Fisher, Challenges and Opportunities of Endovascular Stroke Therapy. Annals of Neurology 79 (2016) 11–17.
  • [2] S. Bhaskar, P. Stanwell, D. Cordato, J. Attia, C. Levi. Reperfusion therapy in acute ischemic stroke: dawn of a new era? BMC Neurology 18 (2018) doi:10.1186/s12883-017-1007-y.
  • [3] G. Nepal, G. Kharel, S.T. Ahamad, B. Basnet. Tenecteplase versus Alteplase for the Management of Acute Ischemic Stroke in a Low-income Country-Nepal: Cost, Efficacy, and Safety. Cureus 10 (2018) e2178. doi: 10.7759/cureus.2178.
  • [4] B.A. Keyt, N.F. Paoni, C.J. Refino, L. Berleau, H. Nguyen, A. Chow, J. Lai, L. Peña, C. Pater, J. Ogez, A faster-acting and more potent form of tissue plasminogen activator. Proceedings of the National Academy of Sciences of the United States of America 91 (1994) 3670-3674.
  • [5] N. Wahlgren, N. Ahmed, A. Dávalos, G.A. Ford, M. Grond, W. Hacke, M.G. Hennerici, M. Kaste, S. Kuelkens, V. Larrue, K.R. Lees, R.O. Roine, L. Soinne, D. Toni, G. Vanhooren, SITS-MOST investigators, Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 369 (2007) 275-282.
  • [6] P. Tanswell, N. Modi, D. Combs, T. Danays, Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clinical Pharmacokinetics 41 (2002) 1229-1245.
  • [7] N. Logallo, C.E. Kvistad, L. Thomassen, Therapeutic Potential of Tenecteplase in the Management of Acute Ischemic Stroke. CNS Drugs 29 (2015) 811-818.
  • [8] Y. Zang, J. Hou, L.Y. Wang, Therapeutic effect of tenecteplase on treatment of cerebral arterial thrombosis: a meta-analysis. European Review for Medical and Pharmacological Sciences 20 (2016) 4369-4379.
  • [9] D. Moher, A. Liberati, J.Tetzlaff, D.G. Altman, The PRISMA Group (2009), Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Medicine (2009) e1000097. doi:10.1371/journal.pmed1000097.
  • [10] E.C. Haley, J.L.P. Thompson, J.C. Grotta, P.D. Lyden, T.G. Hemmen, D.L. Brown, C. Fanale, R. Libman, T.G. Kwiatkowski, R.H. Llinas, S.R. Levine, K.C. Johnston, R. Buchsbaum, G. Levy, B. Levin, Phase IIB/III Trial of Tenecteplase in Acute Ischemic Stroke: Results of a Prematurely Terminated Randomized Clinical Trial. Stroke 41 (2010) 707–711.
  • [11] M. Parsons, N. Spratt, A. Bivard, B. Campbell, K. Chung, F. Miteff, B. O’Brien, C. Bladin, P. McElduff, C. Allen, G. Bateman, G. Donnan, S. Davis, C. Levi, A Randomized Trial of Tenecteplase versus Alteplase for Acute Ischemic Stroke. The New England Journal of Medicine 366 (2012) 1099-1107.
  • [12] X. Huang, B.K. Cheripelli, S. M Lloyd, D. Kalladka, F.C. Moreton, A. Siddiqui, I. Ford, K.W. Muir, Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. The Lancet Neurology 14 (2015) 14: 368–376.
  • [13] N. Logallo, V. Novotny, J. Assmus, C.E. Kvistad, L. Alteheld, O.M. Rønning, B. Thommessen, K.Fr. Amthor, H. Ihle-Hansen, M. Kurz, H. Tobro, K. Kaur, M. Stankiewicz, M. Carlsson, Å. Morsund, T. Idicula, A. Hege Aamodt, C. Lund, H. Næss, U. Waje-Andreassen, L. Thomassen, Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. The Lancet Neurology 16 (2017) 781–788.
  • [14] B.C.V. Campbell, P.J. Mitchell, L. Churilov, N. Yassi, T.J. Kleinig, R.J. Dowling, B. Yan, S.J. Bush, H.M. Dewey, V. Thijs, R. Scroop, M. Simpson, M. Brooks, H. Asadi, T.Y. Wu, D.G. Shah, T. Wijeratne, T. Ang, F. Miteff, C.R. Levi, E. Rodrigues, H. Zhao, P. Salvaris, C. Garcia‑Esperon, P. Bailey, H. Rice, L. de Villiers, H. Brown, K. Redmond, D. Leggett, J.N. Fink, W. Collecutt, A.A. Wong, C. Muller, A. Coulthard, K. Mitchell, J. Clouston, K. Mahady, D. Field, H. Ma, T.G. Phan, W. Chong, R.V. Chandra, L.-A. Slater, M. Krause, T.J. Harrington, K.C. Faulder, B.S. Steinfort, C.F. Bladin, G. Sharma, P.M. Desmond, M.W. Parsons, G.A. Donnan, and S.M. Davis, Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke. The New England Journal of Medicine 378 (2018) 1573-1582.
  • [15] A. Thelengana, D.M. Radhakrishnan, M. Prasad, A. Kumar, K. Prasad, Tenecteplase versus alteplase in acute ischemic stroke: systematic review and meta-analysis. Acta Neurologica Belgica (2018) doi: 10.1007/s13760-018-0933-9
  • [16] W.J. Powers, A.A. Rabinstein, T. Ackerson, O.M. Adeoye, N.C. Bambakidis, K. Becker, J. Biller, M. Brown, B.M. Demaerschalk, B. Hoh, E.C. Jauch, C.S. Kidwell, T.M. Leslie-Mazwi, B. Ovbiagele, P.A. Scott, K.N. Sheth, A.M. Southerland, D.V. Summers, D.L. Tirschwell; American Heart Association Stroke Council, 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 49 (2018) e46-e110. doi: 10.1161/STR.0000000000000158.
  • [17] M. Goyal, A.M. Demchuk, B.K. Menon, M. Eesa, J.L. Rempel, J. Thornton, D. Roy, T.G. Jovin, R.A. Willinsky, B.L. Sapkota, D. Dowlatshahi, D.F. Frei, Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke. The New England Journal of Medicine 372 (2015) 1019-1030.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-5cea3cde-5214-4988-96c0-c0df8dc749a1
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.